IDH1 and astrocytoma (excluding glioblastoma): Favorable prognostic indicators. Patients with IDH-mutant astrocytoma and CNS WHO grade 4 disease have significantly longer survival periods and better treatment responses than do those with IDH-wildtype glioblastoma.